Kamal A. Saeed

Array ( [id] => 18545252 [patent_doc_number] => 11718591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof [patent_app_type] => utility [patent_app_number] => 17/550564 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 25516 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704443 [patent_doc_number] => 20220204449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => BIASED AGONISTS OF OPIOID RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/548288 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922846 [patent_doc_number] => 20240025850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES [patent_app_type] => utility [patent_app_number] => 18/256570 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18278833 [patent_doc_number] => 20230094305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => HUMAN PLASMA KALLIKREIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/543929 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 211050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17543929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20818498 [patent_doc_number] => 12673959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-07 [patent_title] => Polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and use thereof [patent_app_type] => utility [patent_app_number] => 18/268980 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6285 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 407 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18268980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590185 [patent_doc_number] => 11739065 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => FXR (NR1H4) modulating compounds [patent_app_type] => utility [patent_app_number] => 17/537250 [patent_app_country] => US [patent_app_date] => 2021-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19276 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473898 [patent_doc_number] => 20220081402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => CFTR REGULATORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/456368 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17456368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877379 [patent_doc_number] => 20240000748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE [patent_app_type] => utility [patent_app_number] => 18/253025 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18664815 [patent_doc_number] => 11771680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Pyrrole compounds [patent_app_type] => utility [patent_app_number] => 17/455178 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 28459 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518452 [patent_doc_number] => 11708332 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Human plasma kallikrein inhibitors [patent_app_type] => utility [patent_app_number] => 17/526377 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 211124 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17526377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807336 [patent_doc_number] => 20220259171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ENANTIOSELECTIVE CROSS DEHYDROGENATIVE COUPLING REACTIONS AND COMPOUNDS SYNTHESIZED BY THE REACTIONS [patent_app_type] => utility [patent_app_number] => 17/455014 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441734 [patent_doc_number] => 20220062239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => COMPOUNDS USEFUL AS KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/525350 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18210276 [patent_doc_number] => 20230056538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => HUMAN PLASMA KALLIKREIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/522065 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 210939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 276 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666211 [patent_doc_number] => 11773088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => KCNT1 inhibitors and methods of use [patent_app_type] => utility [patent_app_number] => 17/517028 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10149 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19491582 [patent_doc_number] => 12110278 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Selective JAK2 pseudokinase ligands and methods of use [patent_app_type] => utility [patent_app_number] => 17/500622 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 22 [patent_no_of_words] => 28159 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806813 [patent_doc_number] => 20230381146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/248750 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 244 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518481 [patent_doc_number] => 11708361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Processes and intermediates for the preparation of soluble guanylate cyclase stimulators [patent_app_type] => utility [patent_app_number] => 17/497352 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 46524 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17497352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18837647 [patent_doc_number] => 11845708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Method for photocleavage of amide bonds [patent_app_type] => utility [patent_app_number] => 17/486807 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 43 [patent_no_of_words] => 2958 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483521 [patent_doc_number] => 20230210818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => COMPOSITION COMPRISING ORGANOSELENIUM COMPOUND FOR TREATMENT OF SKELETAL MUSCLE ATROPHY [patent_app_type] => utility [patent_app_number] => 17/448755 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17448755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559755 [patent_doc_number] => 11724989 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => MCT4 inhibitors for treating disease [patent_app_type] => utility [patent_app_number] => 17/481660 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23183 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481660 [rel_patent_id] =>[rel_patent_doc_number] =>)